ASTA Comments on FDA Request for Information on Gluten Labeling and Cross-Contact in Packaged Foods
In April 2026, ASTA submitted comments in response to the Food and Drug Administration's (FDA) request for information (RFI) on labeling and cross-contact of gluten in packaged foods, which specifically referenced ingredients that can be declared using collective terms, such as spices. ASTA's comments highlight that no spices inherently contain gluten, note that FDA should take a scientific, risk-based approach to unintended gluten presence, and express support for consistency with existing FDA requirements and harmonization with internal standards for gluten labeling.
04/16/2026 at 12:00 am
0
Related Resources
ASTA Comments on Poppy Seed Practices and Safety
On June 16, 2025, ASTA submitted comments in response to the U.S. Food and Drug Administration's (FDA) Request for Information (RFI) on industry practices on the growing, harvesting, processing, and distribution of poppy seeds. The comments outline the typical poppy seed supply chains, as well as the role of pre- and post-harvest processing steps (e.g., microbiological treatment, baking, etc.) in reducing opiate alkaloid levels in poppy seed-based products.
Coalition Comments to FDA Requesting Sesame Labeling Compliance Date Clarification
ASTA signed onto FBIA coalition comments to the Food and Drug Administration (FDA) in April 2022, requesting that the FDA clarify that the compliance date under the Food Allergy Safety, Treatment, Education, and Research Act (FASTER) means that food products containing sesame must be labeled with a sesame allergen statement on or after January 1, 2021 and that products labeled before that do not need to be in compliance with the FASTER Act.
